LIVECAST Markets Briefs Calendar

Research

News Search AI Market Assistant Charts & News Instrument directory Macro Politics Prediction Markets News Archive

LIVECAST Markets

☀◐Theme

Menu

Home LIVECAST Markets Briefs Calendar News Search AI Market Assistant Charts & News Instrument directory Macro Politics Prediction Markets News Archive Account

Home News ArchiveMi Material Offerings to Raise S$215.0M

Live News EQUITY FLASH M impact Oct 19, 2026, 05:23 AM UTC

Mi Material Offerings to Raise S$215.0M

SquawkNews Desk

Use this page

Share or save this market-moving headline as a permanent SquawkNews URL. The live feed continues at /news.

Open live news feed Browse news archive Browse news categories Search related coverage

Related tickers

MI

Related stories

Roche Says Divarasib Cut Lung Cancer Death Risk 44% in Phase III Trial Roche said its experimental drug divarasib reduced the risk of death by 44% versus existing treatments in a Phase III study of previously treated patients with KRAS G12C-mutated no M impact | EQUITY | Oct 25, 2026, 06:29 PM UTC SoftBank Plans $50 Billion AI Investment in Malaysia M impact | EQUITY | Oct 25, 2026, 05:18 PM UTC India’s Top Firms Lose Rs 1.56 Trillion in Market Value Eight of India’s 10 most valuable listed companies lost a combined Rs 1.56 lakh crore in market value last week. The Sensex fell 1,605.44 points and the Nifty declined 546.15 point M impact | EQUITY | Oct 25, 2026, 04:05 PM UTC Ivonescimab Shows Overall Survival Benefit in Phase III BTC Trial Summit Therapeutics said partner Akeso’s Phase III HARMONi-GI1 trial found ivonescimab plus chemotherapy improved overall survival versus durvalumab plus chemotherapy in first-line M impact | EQUITY | Oct 25, 2026, 03:52 PM UTC Genentech Reports Phase III Divarasib Efficacy Results in Lung Cancer Genentech said its Phase III KRASCENDO 1 study found investigational divarasib more efficacious than current standard of care in previously treated KRAS G12C-mutated lung cancer. M impact | EQUITY | Oct 25, 2026, 03:30 PM UTC AstraZeneca Drug Extends Survival in Late-Stage Stomach Cancer Study AstraZeneca’s experimental drug sone-ve helped patients with advanced stomach cancer live longer than analysts had expected, according to late-stage trial data presented Sunday. M impact | EQUITY | Oct 25, 2026, 03:30 PM UTC

SQUAWK/NEWS

Independent financial newsroom. Editorial expertise and proprietary AI. Paid LiveCast brings live headlines, chart context and priority audio to your trading day. Free research tools remain available.

LiveCast passes from $15 · Institutional API access.

Start LiveCast

News & Research

Open LiveCast
Session Briefs
Macro
Politics
Prediction Markets
News Archive

Markets & Tools

Charts & News
Markets Overview
US Stocks
Market Movers
Economic Calendar
Policy Calendar
AI Market Assistant
News Search
Instrument Directory

Guides

Charts & News Guide
How LiveCast Works
What Is an Audio Squawk?
Why News Moves Markets
News for Traders
How to Trade the News

Plans & API

Plans & Pricing
Institutional API
RSS Feed

Company

About
Why SquawkNews
Newsroom
Editorial Standards
Corrections
Contact us

© 2026 SquawkNews

Privacy Policy Terms of Use

SquawkNews publishes market information and context. It does not provide investment advice or trade recommendations.